FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366205211> ?p ?o ?g. }

• W4366205211 endingPage "419" @default.
• W4366205211 startingPage "411" @default.
• W4366205211 abstract "Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease frequently coexisting with other type 2 conditions including asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD). Coexisting asthma leads to increased CRSwNP symptom burden. Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin-4 and -13, demonstrated efficacy in adults with severe CRSwNP in the Phase 3 SINUS-24 (NCT02912468) and SINUS-52 (NCT02898454) studies, including in patients with coexisting asthma/NSAID-ERD. However, the impact of different asthma characteristics on dupilumab treatment in this population is unknown. We report CRSwNP and asthma outcomes with dupilumab in patients with CRSwNP and coexisting asthma according to baseline asthma characteristics.Change from baseline at Week 24 (pooled studies) and Week 52 (SINUS-52) in CRSwNP outcomes (nasal polyp score, nasal congestion, 22-item Sino-Nasal Outcome Test [SNOT-22], loss of smell score, University of Pennsylvania Smell Identification Test) and asthma outcomes (5-item Asthma Control Questionnaire [ACQ-5], pre-bronchodilator forced expiratory volume in 1 second [FEV1]) were analyzed post hoc for placebo and dupilumab 300 mg every 2 weeks according to baseline blood eosinophils ≥150/≥300 cells/µL, ACQ-5 scores <1.5/≥1.5, and FEV1 <80%.In the pooled studies, 428/724 patients (59.1%) had coexisting asthma, of which 181/428 (42.3%) had coexisting NSAID-ERD. Dupilumab significantly improved all CRSwNP and asthma outcomes vs placebo at Week 24 (P < 0.001) regardless of baseline eosinophil or ACQ-5 category, or FEV1 <80%. Similar magnitude of improvement was seen at Week 52 (SINUS-52) and in patients with NSAID-ERD (pooled studies, Week 24). By Week 24, improvements with dupilumab exceeded the minimum clinically important differences for ACQ-5 and SNOT-22 in 35.2% to 74.2% and 72.0% to 78.7% of patients, respectively.Dupilumab improved CRSwNP outcomes in patients with CRSwNP and coexisting asthma, and improved asthma outcomes, regardless of differences in baseline asthma characteristics." @default.
• W4366205211 created "2023-04-19" @default.
• W4366205211 creator A5011255987 @default.
• W4366205211 creator A5011502862 @default.
• W4366205211 creator A5016354363 @default.
• W4366205211 creator A5017711682 @default.
• W4366205211 creator A5029342656 @default.
• W4366205211 creator A5037227971 @default.
• W4366205211 creator A5044980958 @default.
• W4366205211 creator A5059328493 @default.
• W4366205211 creator A5089685782 @default.
• W4366205211 date "2023-04-01" @default.
• W4366205211 modified "2023-10-03" @default.
• W4366205211 title "Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics" @default.
• W4366205211 cites W2030674948 @default.
• W4366205211 cites W2039439214 @default.
• W4366205211 cites W2086769142 @default.
• W4366205211 cites W2200308911 @default.
• W4366205211 cites W2205538181 @default.
• W4366205211 cites W2346391788 @default.
• W4366205211 cites W2509404831 @default.
• W4366205211 cites W2594033175 @default.
• W4366205211 cites W2801587651 @default.
• W4366205211 cites W2885029018 @default.
• W4366205211 cites W2891218618 @default.
• W4366205211 cites W2912061875 @default.
• W4366205211 cites W2912558194 @default.
• W4366205211 cites W2962719006 @default.
• W4366205211 cites W2973437633 @default.
• W4366205211 cites W2996174934 @default.
• W4366205211 cites W3030200031 @default.
• W4366205211 cites W3037468357 @default.
• W4366205211 cites W3081076625 @default.
• W4366205211 cites W3093213532 @default.
• W4366205211 cites W3101343105 @default.
• W4366205211 cites W3102369731 @default.
• W4366205211 cites W3111544698 @default.
• W4366205211 cites W3122251071 @default.
• W4366205211 cites W3126598211 @default.
• W4366205211 cites W3128930788 @default.
• W4366205211 cites W3136140292 @default.
• W4366205211 cites W3159709772 @default.
• W4366205211 cites W3165365105 @default.
• W4366205211 cites W3173748714 @default.
• W4366205211 cites W3190066153 @default.
• W4366205211 cites W3194122667 @default.
• W4366205211 cites W3206170968 @default.
• W4366205211 cites W4225318520 @default.
• W4366205211 cites W4229077018 @default.
• W4366205211 cites W4280586626 @default.
• W4366205211 cites W4283653389 @default.
• W4366205211 cites W4285719527 @default.
• W4366205211 cites W4293516800 @default.
• W4366205211 cites W4294699767 @default.
• W4366205211 cites W4318220563 @default.
• W4366205211 doi "https://doi.org/10.2147/jaa.s391896" @default.
• W4366205211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37096015" @default.
• W4366205211 hasPublicationYear "2023" @default.
• W4366205211 type Work @default.
• W4366205211 citedByCount "1" @default.
• W4366205211 countsByYear W43662052112023 @default.
• W4366205211 crossrefType "journal-article" @default.
• W4366205211 hasAuthorship W4366205211A5011255987 @default.
• W4366205211 hasAuthorship W4366205211A5011502862 @default.
• W4366205211 hasAuthorship W4366205211A5016354363 @default.
• W4366205211 hasAuthorship W4366205211A5017711682 @default.
• W4366205211 hasAuthorship W4366205211A5029342656 @default.
• W4366205211 hasAuthorship W4366205211A5037227971 @default.
• W4366205211 hasAuthorship W4366205211A5044980958 @default.
• W4366205211 hasAuthorship W4366205211A5059328493 @default.
• W4366205211 hasAuthorship W4366205211A5089685782 @default.
• W4366205211 hasBestOaLocation W43662052111 @default.
• W4366205211 hasConcept C126322002 @default.
• W4366205211 hasConcept C141071460 @default.
• W4366205211 hasConcept C142724271 @default.
• W4366205211 hasConcept C203014093 @default.
• W4366205211 hasConcept C204787440 @default.
• W4366205211 hasConcept C27081682 @default.
• W4366205211 hasConcept C2776042228 @default.
• W4366205211 hasConcept C2776178081 @default.
• W4366205211 hasConcept C2776238763 @default.
• W4366205211 hasConcept C2777037409 @default.
• W4366205211 hasConcept C2777714996 @default.
• W4366205211 hasConcept C2777768476 @default.
• W4366205211 hasConcept C2777844070 @default.
• W4366205211 hasConcept C2778311950 @default.
• W4366205211 hasConcept C2779824493 @default.
• W4366205211 hasConcept C2780769369 @default.
• W4366205211 hasConcept C2781142857 @default.
• W4366205211 hasConcept C2781390199 @default.
• W4366205211 hasConcept C71924100 @default.
• W4366205211 hasConcept C90924648 @default.
• W4366205211 hasConceptScore W4366205211C126322002 @default.
• W4366205211 hasConceptScore W4366205211C141071460 @default.
• W4366205211 hasConceptScore W4366205211C142724271 @default.
• W4366205211 hasConceptScore W4366205211C203014093 @default.
• W4366205211 hasConceptScore W4366205211C204787440 @default.
• W4366205211 hasConceptScore W4366205211C27081682 @default.

• next